By Jack Simony
The U.S. Solicitor General wants to the U.S. Supreme Court to reject an appeal by drug companies in a generic Reglan lawsuit filed over a claim about failing to adequately warn about a rare movement order associated with the drug, AboutLawsuits reported.
“The court of appeals correctly held that respondent’s failure-to-warn claims are not categorically preempted, because a generic manufacturer, can (and indeed, must) inform FDA of new information about risks that may require a change in the labeling of its drug,” the Solicitor General stated, according to the website.
– By Jack Simony